Tanya Siddiqi, MD, Discusses the TRANSCEND CLL-004 Trial
December 6, 2019
Tanya Siddiqi, MD, discussed the CAR T-cell trial ahead of the ASH Annual Meeting & Exposition in an interview with CancerNetwork®.
Recent Content
FDA Approves FoundationOne CDx as Companion Diagnostic for Alpelisib
December 5, 2019
The FDA approved FoundationOne CDx as a companion diagnostic for alpelisib in combination with fulvestrant for the treatment of men and postmenopausal women with HR+/HER2- PIK3CA-mutated breast cancer.
Ashish Saxena, MD, PhD Discusses Immunotherapy Drugs Effect on OS in Lung Cancer
December 5, 2019
Ashish Saxena, MD, PhD, from Weill Cornell Medicine, discussed how immunotherapy may lead to an increase in overall survival of patients at the Annual New York Lung Cancers Symposium®.
Balazs Halmos, MD, MS, Discusses Metastatic Non-Small Cell Lung Cancer Advancements
December 5, 2019
Balazs Halmos, MD, MS, from Montefiore Albert Einstein Cancer Center, discussed advancements in treatment of metastatic non-small cell lung cancer at the Annual New York Lung Cancers Symposium®.
Chemical Straighteners and Permanent Hair Dyes May Increase Breast Cancer Risk
December 5, 2019
Research suggests that there is an association between breast cancer risk and the use of chemical straighteners and permanent hair dyes.
Phase I/II Studies of Annamycin in Acute Myeloid Leukemia Report Positive Interim Results
December 4, 2019
Additional positive interim safety and efficacy data were reported for annamycin in the treatment of patients with relapsed or refractory acute myeloid leukemia.
FDA Grants Breakthrough Therapy Designation to Abatacept for Acute GVHD Prevention
December 4, 2019
The FDA granted a breakthrough therapy designation to abatacept for the prevention of moderate to severe acute graft-versus-host disease in hematopoietic stem cell transplants from unrelated donors.
Kevin M. Sullivan, MD, Discusses Treatment Expansion in Lung Cancer
December 4, 2019
Kevin M. Sullivan, MD, from the Northwell Health Cancer Institute, discussed how the options for treatment of patients with lung cancer have expanded greatly at the Annual New York Lung Cancers Symposium®.
FDA Approves Frontline Atezolizumab Plus Chemo for Metastatic Non-Squamous NSCLC
December 4, 2019
The FDA approved atezolizumab in combination with chemotherapy for the first-line treatment of adults with metastatic non-squamous non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations.
Addressing the Challenges of Treatment Sequencing in Multiple Myeloma
December 3, 2019
Sham Mailankody, MBBS, discussed the challenge of determining an optimal sequence of treatments in patients with relapsed/refractory multiple myeloma, and how head-to-head studies can help.
